Jane E. Carleton

Jane Carleton practices at Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York.

Jane Carleton's NPI, 1285764670, was assigned on March 6, 2007. Jane Carleton graduated from UMass Chan Medical School in 1991. Jane Carleton holds New York license 222892.

Jane Carleton's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center, at 450 Lakeville Rd, Lake Success, NY 11042. The practice phone is (516) 734-8281.

Jane Carleton's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York. Jane Carleton is also affiliated with Long Island Jewish Medical Center. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Jane Carleton to 1 more hospital, 2 group practices and clinics, 1 clinical lab and 1 medical group, each named with a free account. Jane Carleton's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Jane Carleton practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Jane Carleton's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Jane Carleton is board certified in medical oncology by the American Board of Internal Medicine. Jane Carleton is licensed in New York.

Dmand AI lists breast cancer, lung cancer and lymphoma among the conditions Jane Carleton treats.

CMS data shows 1,064 Medicare services from Jane Carleton across 6 procedure codes in 2024, for 355 Medicare patients. Medicare paid $86,630 for them.

CMS counts 355 Medicare patients who saw Jane Carleton in 2024. The largest group is 65 to 74, with 165 patients. 75% of them have cancer, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Jane Carleton's median patient age at 67, with 90% women.

In 2024, Jane Carleton wrote 992 Medicare Part D claims for 265 patients. 84% of them were for generic drugs. CMS names the drug for 838 of them, across 14 drugs with 11 or more claims each, at $1,753,946 in total drug cost. In 2023, CMS named 764 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Jane Carleton for performance year 2024, reported as part of a group. Jane Carleton accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Jane Carleton as offering telehealth.

Dmand AI links 2 papers to Jane Carleton, published from 2009 to 2016. Jane Carleton's most frequent co-authors are James R. Jett, MD, Corey J. Langer, MD and Primo Nery Lara, MD.

Dmand AI links Jane Carleton to 3 clinical trials, 3 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating, Lung Neoplasms and Breast Carcinoma In Situ.

CMS Open Payments shows 1 general payment to Jane Carleton from 1 drug or device company in 2021. Education make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $12.

Jane Carleton graduated from UMass Chan Medical School in 1991. Jane Carleton is a member of ASCO.

Jane Carleton is in network with 16 carriers, including Elevance, United Healthcare and Aetna. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.